J. Bastin, F. Aubey, A. Rotig, A. Munnich, and F. Djouadi, Activation of peroxisome proliferator-activated receptor pathway stimulates the mitochondrial respiratory chain and can correct deficiencies in patients' cells lacking its components, J Clin Endocrinol Metab, vol.93, pp.1433-1441, 2008.

J. P. Bonnefont, J. Bastin, P. Laforet, F. Aubey, A. Mogenet et al., Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency, 2010.

, Clin Pharmacol Ther, vol.88, pp.101-108

T. Hays, I. Rusyn, A. M. Burns, M. J. Kennett, J. M. Ward et al., Role of peroxisome proliferator-activated receptor-alpha (PPARalpha) in bezafibrateinduced hepatocarcinogenesis and cholestasis, Carcinogenesis, vol.26, pp.219-227, 2005.

T. Nakajima, N. Tanaka, H. Kanbe, A. Hara, Y. Kamijo et al., Bezafibrate at clinically relevant doses decreases serum/liver triglycerides via down-regulation of sterol regulatory element-binding protein-1c in mice: a novel peroxisome proliferator-activated receptor alpha-independent mechanism, Mol Pharmacol, vol.75, pp.782-792, 2009.

C. Viscomi, E. Bottani, G. Civiletto, R. Cerutti, M. Moggio et al.,

C. Lamperti and M. Zeviani, In Vivo Correction of COX Deficiency by Activation of the AMPK/PGC-1alpha Axis, Cell Metab, vol.14, pp.80-90, 2011.